Filtered By:
Condition: Diabetes
Education: Learning

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 345 results found since Jan 2013.

Characteristic of Clinical Studies on Baduanjin during 2000-2019: A Comprehensive Review.
Authors: Zhou J, Yu Y, Cao B, Li X, Wu M, Wen T, Xiong Y, Jia J, Zhao Y Abstract To date, a growing number of clinical studies have demonstrated the safety and health benefits from Baduanjin intervention. Based on this, our objective is to systematically retrieve and summarize the clinical studies on Baduanjin, with a view to providing more evidence-based evidence in support of the application of Baduanjin for healthcare, and to identify the shortcomings of existing research and provide feasibility suggest for further clinical research. Both four English language and four Chinese language electronic databases were ...
Source: Evidence-based Complementary and Alternative Medicine - November 6, 2020 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids
Conclusions: The circulating miRNA profile complements conventional risk factors to identify specific cardiovascular risk patterns among patients receiving maintenance HD.
Source: Theranostics - October 3, 2020 Category: Molecular Biology Authors: David de Gonzalo-Calvo, Pablo Mart í nez-Camblor, Christian B ä r, Kevin Duarte, Nicolas Girerd, Bengt Fellstr ö m, Roland E. Schmieder, Alan G. Jardine, Ziad A. Massy, Hallvard Holdaas, Patrick Rossignol, Faiez Zannad, Thomas Thum Tags: Research Paper Source Type: research

Featured Reviews: Behavioural activation therapy for depression
How well does behavioural activation therapy work for depression in adults?  And what about the effects of this treatment on depression for adults with long‐term physical conditions? Two new Cochrane systematic reviews look at the available evidence.Depression is a common mental health problem. It can cause a persistent feeling of sadness and loss of interest in people, activities, and things that were once enjoyable. Treatments for depression include psychological therapies (talking therapies). Two reviews recently published byCochrane Common Mental Disordersfocus on a type of psychological therapy called behavioural a...
Source: Cochrane News and Events - September 9, 2020 Category: Information Technology Authors: Muriah Umoquit Source Type: news

What Are the Main Acyanotic Congenital Heart Diseases?
Discussion Congenital heart diseases (CHD) are malformations of the heart and great vessels. It occurs in about 5-8/1000 live births. Cyanotic congenital heart disease is often noted perinatally because of cyanosis, respiratory distress and/or poor feeding or other distress type problems. A review can be found here. Acyanotic congenital heart disease (ACHD) can present at birth but often is seen in older children or adults unless the lesions are severe, especially obstructive lesions. Severe lesions may also cause cyanosis and distress type problems in patients also. Shunting lesions cause problems by diverting blood flo...
Source: PediatricEducation.org - August 17, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Glucose transporters in brain in health and disease.
Abstract Energy demand of neurons in brain that is covered by glucose supply from the blood is ensured by glucose transporters in capillaries and brain cells. In brain, the facilitative diffusion glucose transporters GLUT1-6 and GLUT8, and the Na+-D-glucose cotransporters SGLT1 are expressed. The glucose transporters mediate uptake of D-glucose across the blood-brain barrier and delivery of D-glucose to astrocytes and neurons. They are critically involved in regulatory adaptations to varying energy demands in response to differing neuronal activities and glucose supply. In this review, a comprehensive overview abo...
Source: Pflugers Archiv : European Journal of Physiology - August 12, 2020 Category: Physiology Authors: Koepsell H Tags: Pflugers Arch Source Type: research

Modern machine-learning can support diagnostic differentiation of central and peripheral acute vestibular disorders
ConclusionsEstablished clinical scores (such as HINTS) provide a valuable baseline assessment for stroke detection in acute vestibular syndromes. In addition, machine-learning methods may have the potential to increase sensitivity and selectivity in the establishment of a correct diagnosis.
Source: Journal of Neurology - June 10, 2020 Category: Neurology Source Type: research

AHA News: After Diabetes, Stroke and Heart Attack, She ' s Learning to ' Fight Smart '
Title: AHA News: After Diabetes, Stroke and Heart Attack, She ' s Learning to ' Fight Smart 'Category: Health NewsCreated: 5/21/2020 12:00:00 AMLast Editorial Review: 5/22/2020 12:00:00 AM
Source: MedicineNet Heart General - May 22, 2020 Category: Cardiology Source Type: news

Effects of Mulberry on the Central Nervous System: A Literature Review.
CONCLUSION: Mulberry species proved beneficial to many neurological functions in animal models. The active ingredients of each species, especially M. alba, should be deeper studied for screening potentially candidates for future treatments. PMID: 32379591 [PubMed - as supplied by publisher]
Source: Current Neuropharmacology - May 5, 2020 Category: Drugs & Pharmacology Authors: Tam DNH, Nam NH, Elhady MT, Tran L, Hassan OG, Sadik M, Tien PTM, Elshafei GA, Huy NT Tags: Curr Neuropharmacol Source Type: research

Deep learning approach for diabetes prediction using PIMA Indian dataset
ConclusionThe outcome of the study confirms that DL provides the best results with the most promising extracted features. DL achieves the accuracy of 98.07% which can be used for further development of the automatic prognosis tool. The accuracy of the DL approach can further be enhanced by including the omics data for prediction of the onset of the disease.
Source: Journal of Diabetes and Metabolic Disorders - April 13, 2020 Category: Endocrinology Source Type: research

Gospel Music: A Catalyst for Retention, Engagement, and Positive Health Outcomes for African Americans in a Cardiovascular Prevention and Treatment Program.
Conclusions: The addition of a gospel music program as a catalyst for increase engagement in a sustainable, healthy lifestyle program warrants further consideration and additional study in African American churches. PMID: 32277749 [PubMed - as supplied by publisher]
Source: Advances in Mind Body Medicine - April 12, 2020 Category: Psychiatry Tags: Adv Mind Body Med Source Type: research

Medical Management for Secondary Stroke Prevention
This article reviews the evidence base and recommendations for medical management for secondary stroke prevention. RECENT FINDINGS Recent developments for secondary stroke prevention include evidence to support the use of short-term dual antiplatelet therapy after minor stroke and transient ischemic attack, direct oral anticoagulants for nonvalvular atrial fibrillation, reversal agents for direct oral anticoagulant–associated hemorrhage, and aspirin rather than presumptive anticoagulation with a direct oral anticoagulant for embolic stroke of undetermined source. SUMMARY Most strokes are preventable. The mainstays ...
Source: CONTINUUM: Lifelong Learning in Neurology - April 1, 2020 Category: Neurology Tags: REVIEW ARTICLES Source Type: research

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit using...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news